Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform on Gilead Sciences (GILD) Amid 'Potential HHS HIV Funding Cuts'

March 19, 2025 10:05 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $115.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles